狼疮性肾炎:未满足的需求与不断发展的解决方案
本文讨论狼疮性肾炎免疫治疗进展下仍存在的未满足需求,提出应区分免疫活动性与不可逆肾损伤的组织学标志,正确解读残余蛋白尿需区分免疫活动与肾小球高滤过,并倡导克隆导向治疗及用补体抑制替代早期糖皮质激素。
要点
- 残余蛋白尿的解读需区分免疫活动与肾小球高滤过,必要时重复活检。
- 按方案活检仍显示第一年内发生不可逆肾损伤。
- 作者倡导克隆导向治疗,充分抑制淋巴组织内记忆B/T细胞及骨髓长寿命浆细胞。
核心结论
- 狼疮性肾炎免疫治疗日益丰富,但仍存在重要未满足需求。
- 作者倡导克隆导向治疗以充分抑制自身反应性记忆B/T细胞及骨髓长寿命浆细胞。
- 作者认为补体系统即刻抑制可能满足这一未满足需求,甚至可能最终替代早期糖皮质激素治疗。
- 作者认为用非口服、非毒性药物替代类固醇、霉酚酸酯和钙调神经磷酸酶抑制剂是未来十年的目标。
- 作者认为获得狼疮性肾炎孤儿药资格将加速进展,并得到最新患病率数据的支持。
研究设计与样本
- 本文为综述,讨论狼疮性肾炎未满足需求与不断发展的解决方案。
主要发现
- 尽管采用现代三联免疫治疗,按方案活检仍记录到第一年内发生不可逆损伤。
- 残余蛋白尿的正确解读需要通过重复活检等方式区分免疫活动与肾小球高滤过。
- 多种靶向B细胞和浆细胞的治疗正逐渐可用,其肠外给药途径还可能避免口服药物不依从。
临床怎么用
- 作者倡导关注触发免疫治疗的组织学免疫活动标志与需要慢性肾脏病管理的不可逆肾损伤标志。
- 作者倡导克隆导向治疗,充分抑制淋巴组织内自身反应性记忆B和T细胞及骨髓中维持SLE活动、驱动疾病发作的长寿命浆细胞。
- 作者认为补体系统即刻抑制可能满足未满足需求,甚至可能帮助最终替代早期糖皮质激素治疗。
- 作者认为用非口服、非毒性药物替代类固醇、霉酚酸酯和钙调神经磷酸酶抑制剂是未来十年的目标。
- 作者认为获得狼疮性肾炎孤儿药资格将加速进展。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lupus nephritis (LN) is seeing more and more enriching immunotherapies, but important unmet needs remain. Here, we discuss how to focus on histologic signs of immunologic activity triggering immunotherapy versus signs of irreversible kidney injury requiring care for CKD. In addition, the correct interpretation of residual proteinuria requires dissecting immunologic activity from glomerular hyperfiltration, e.g ., by repeat biopsy. Despite modern triple immunotherapy, per-protocol biopsies still document irreversible injury to occur in the first year. Immediate inhibition of the complement system may address this unmet need and may even help to ultimately replace early glucocorticoid therapy. We advocate the concept of a clone-directed therapy to sufficiently suppress the autoreactive clones of memory B and T cells inside the lymphoid tissues as well as the long-lived plasma cells in the bone marrow that maintain activity of SLE and drive disease flares. Numerous B-cell and plasma cell-targeting therapies are gradually becoming available, and their parenteral route of application may also avoid oral drug nonadherence. Replacing oral and toxic medications such as steroids, mycophenolate, and calcineurin inhibitors is now a goal for the next decade. Obtaining orphan disease designation for LN would accelerate progress and is supported by latest data on LN prevalence. With these conceptual and management improvements, LN, once "complex" and frequently fatal, may become easy-to-manage as other autoimmune diseases.
引用
- Abinti M, Patricio-Liebana M, Anders HJ, et al. Lupus Nephritis: Unmet Needs and Evolving Solutions. Clin J Am Soc Nephrol. 2025. PMID: 40788686. doi:10.2215/CJN.0000000858
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。